Yuan-Gao Liao

Yuan-Gao Liao

Auto-generated profile, based on publicly available information

Yuan-Gao Liao

Department of Neurology, Huanggang Central Hospital, Huanggang, Hubei, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Folia Neuropathologica
Verified
Journal Article
Open access
YLYuangao Liao
Yuangao Liao
YGYong Gu
Yong Gu
JWJin-hua Wang
Jin-hua Wang
YTYu Tian
Yu Tian
XNXiaohong Ni
Xiaohong Ni
GXGuangming Xia
Guangming Xia
Parkinson’s disease (PD) is characterized by microglia activation that leads to neuroinflammation. Heat shock transcription factor 1 (HSF1) is known to exert neuroprotective effects on neurodegenerative diseases. This study sought to analyse the role and mechanism of HSF1 in PD-induced...

23 September 2022 in Medicine
Verified
Journal Article
Open access
YLYuan-Gao Liao
Yuan-Gao Liao
FHFeng-Zhen Huang
Feng-Zhen Huang
XNXiao-Hong Ni
Xiao-Hong Ni
HKHong-Yan Bs Ke
Hong-Yan Bs Ke
YTYu Tian
Yu Tian
GCGui-Hai Chen
Gui-Hai Chen
Schedule exercise therapy (SET) is a novel nonpharmacological intervention for the treatment of chronic insomnia disorder (CID). The aim of this study was to explore the effects of SET on CID. Methods: One hundred and eighteen CID were recruited and randomized into medication (MED) or medication combined with SET (MSET) groups. Over 12 observational weeks, sleep and mood status were evaluated using the Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS), Self-rating Depression Scale (SDS), and Self-rating Anxiety Scale (SAS). At the end of the observational period, the rates of clinically effective hypnotic use were calculated. At 12 weeks, the PSQI progressively decreased for all subjects combined (P < .001) as well as ISI (P < .001), ESS (P < .001), SDS (P < .001), and SAS (P < .001). The decreases in PSQI (P < .05), ISI (P < .05), SDS (P < .01), and SAS (P < .05) in the MSET group were significantly larger than those in the MED group, but not the same as those in the ESS group (P > .05). At the trial endpoint, the clinically effective rate was significantly higher (P < .05) and the hypnotic usage rate was lower (P < .05) in the MSET group than in the MED group. SET may be an effective treatment for insomnia in patients with CID.